BIOMARIN PHARMACEUTICAL INC - Common Stock (BMRN)

CUSIP: 09061G101

Q2 2024 13F Holders as of 30 Jun 2024

Holder snapshot 7 signals
Share change
-772,337
Put/Call ratio
72%
SEC-reported price per share
$82.33
Indexed holders
555
Value change
-$88,804,857
Number of buys
277
Open additional details 1 more signal available
Number of sells
270
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
193,733,090

Security key

09061G101

Report period

Q2 2024

Indexed institutions

555

Top holders

10

Ownership snapshot

Top reported holders of BMRN - BIOMARIN PHARMACEUTICAL INC - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
PRIMECAP MANAGEMENT CO/CA/
Disclosed value leader
PRIMECAP MANAGEMENT CO/CA/
Comparable rows
0/15
Latest evidence
31 Mar 2024
13F Highest disclosed value: $1,634,471,589 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

PRIMECAP MANAGEMENT CO/CA/ has the largest disclosed position value at $1.63B.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens PRIMECAP MANAGEMENT CO/CA/'s linked filing trail.
Disclosed position value Top 5
PRIMECAP MANAGEMENT CO/CA/ $1.63B
VANGUARD GROUP INC $1.58B
BlackRock Finance, Inc. $1.26B
DODGE & COX $1.22B
STATE STREET CORP $602.23M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
PRIMECAP MANAGEMENT CO/CA/
13F
Company
13F
—
denominator unverified
$1,634,471,589
18,713,895 shares
— 31 Mar 2024
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$1,582,348,213
18,117,108 shares
— 31 Mar 2024
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$1,264,577,520
14,478,790 shares
— 31 Mar 2024
DODGE & COX
13F
Company
13F
—
denominator unverified
$1,222,143,642
13,992,943 shares
— 31 Mar 2024
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$602,228,078
6,895,215 shares
— 31 Mar 2024
Capital Research Global Investors
13F
Company
13F
—
denominator unverified
$569,514,532
6,520,661 shares
— 31 Mar 2024
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q2 2024

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
555
Shares
184,765,128
Indexed holders
555
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q2 2024 vs Q1 2024 Across Filers

Q1 2024 indexed holders
550
Q2 2024 indexed holders
555
Indexed holder difference
5
Investor Q1 2024 Shares Q2 2024 Shares Share Diff Share Chg % Q1 2024 value Q2 2024 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .